Situs Slot Gacor Slot Gacor Gampang Menang Situs Slot Gacor https://gms.dpe.go.th/mobile/public/admin/ckfinder/plugins/fileeditor/situs-judi-slot-terbaik-dan-terpercaya-no-1/ http://portalsewa.mais.gov.my/img/icons/largest/slot-online-gacor-terbaru/ https://new.c.mi.com/th/post/340006/SBOBET__Agen_Judi_Bola_Online_SBOBET88_Resmi_Indon https://new.c.mi.com/th/post/338489/SBOBET__Agen_Bola_Resmi_Layanan_Taruhan_Online_Ter https://new.c.mi.com/th/post/338479/Agen_SBOBET_Indonesia_Terpercaya__Link_Daftar_SBOB https://new.c.mi.com/th/post/338474/Situs_Judi_Bola_Online_Sbobet_dan_Agen_Bola_Terper https://new.c.mi.com/th/post/737547/SBOBET__AGEN_SBOBET_INDONESIA_LOGIN_MOBILE_ONLINE_ https://new.c.mi.com/th/post/735520/SBOBET__Link_Bandar_Sbobet88_Indonesia_Terpercaya_ https://new.c.mi.com/th/post/738763/DAFTAR_SBOBET_88_BOLA_TERMURAH_DAN_TERLENGKAP_BERS https://new.c.mi.com/th/post/735126/SBOBET_MOBILE__Daftar_Judi_Bola_Online__SBOBET88_C https://new.c.mi.com/th/post/737542/SBOBET__Daftar_Judi_Bola_Online__SBOBET88_Casino__ https://new.c.mi.com/th/post/733494/Agen_SBOBET_Indonesia_Terpercaya__Link_Daftar_SBOB
Business

Under hub-and-spoke biotechnology, serial entrepreneurs launch new startup in hopes of creating gene therapy for the eye – Endpoints News




In late July, Sangamo’s former R&D chief Adrian Woolfson, who left the biotech when it split its R&D, launched its own gene therapy outfit. Replay’s primary platform was an HSV vector that, as a hub-and-spoke biotech, it said it built four different companies around.

Now the first of these four companies is out of the bag, with a co-founding team of four academics who have deep biotech experience. Under the name Eudora, the company Replay will address three eye diseases: retinitis pigmentosa, Stargardt disease and Usher syndrome type 1B.

Under hub-and-spoke biotechnology, serial entrepreneurs launch new startup in hopes of creating gene therapy for the eye – Endpoints News

Continue reading Endpoints with a free subscription

Unlock this story immediately and join over 1[ads1]52,500 biopharma professionals who read Endpoints daily – and it’s free.




Source link

Back to top button